Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Sanofi-Aventis’ Jevtana is notable for its 11-week expedited review, which made it as the speediest approval of 2010.
Advertisement

Related Content

The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival
Accelerated Evolution Of Prostate Cancer Therapy Shaped Xtandi Review
Review Of Reviews: Drug Review Profiles Of 2011
The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
GPC Biotech To Resubmit Orplatna With Overall Survival Data
FDA Takes More Conservative Approach To Quantifying Oncologic Benefit

Topics

Advertisement
UsernamePublicRestriction

Register

PS004704

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel